北京大学学报（医学版） ›› 2020, Vol. 52 ›› Issue (3): 597-602. doi: 10.19723/j.issn.1671-167X.2020.03.031
中性粒细胞与淋巴细胞比例对评估接受过继性细胞免疫治疗的晚期胰腺癌患者预后的临床意义
姜妮,乔国梁,王小利,周心娜,周蕾,宋雨光,赵艳杰,任军(
)
- 首都医科大学附属北京世纪坛医院肿瘤内科,肿瘤治疗性疫苗北京市重点实验室,北京 100038
中图分类号:
- R730.51
| [1] |
Del Chiaro M, Segersvard R, Lohr M, et al. Early detection and prevention of pancreatic cancer: is it really possible today?[J]. World J Gastroenterol, 2014,20(34):12118-12131.
doi: 10.3748/wjg.v20.i34.12118 pmid: 25232247 |
| [2] | Yabar CS, Winter JM. Pancreatic cancer: A review[J]. Gas-troenterol Clin North Am, 2016,45(3):429-445. |
| [3] | Zhang Y, Zhang X, Zhang A, et al. Clinical applications of dendritic cells-cytokine-induced killer cells mediated immunotherapy for pancreatic cancer: an up-to-date meta-analysis[J]. Onco Targets Ther, 2017,10:4173-4192. |
| [4] | Lin M, Liang S, Jiang F, et al. 2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage Ⅳ breast cancer[J]. Immunol Lett, 2017,183(3):37-43. |
| [5] |
Koizumi W, Kurihara M, Nakano S, et al. Phase Ⅱ study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group[J]. Oncology, 2000,58(3):191-197.
pmid: 10765119 |
| [6] | Hagihara K, Ikeda M, Maeda S, et al. Effectiveness of irinotecan, S-1, and bevacizumab for rectal cancer with lung and skin metastases after adjuvant chemotherapy[J]. Gan To Kagaku Ryoho, 2016,43(12):2313-2315. |
| [7] |
Ueno H, Ioka T, Ikeda M, et al. Randomized phase Ⅲ study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study[J]. J Clin Oncol, 2013,31(13):1640-1648.
pmid: 23547081 |
| [8] |
Morizane C, Okusaka T, Furuse J, et al. A phase Ⅱ study of S-1 in gemcitabine-refractory metastatic pancreatic cancer[J]. Cancer Chemother Pharmacol, 2009,63(2):313-319.
doi: 10.1007/s00280-008-0741-7 |
| [9] | Jiang N, Qiao G, Wang X-L, et al. Dendritic cell/cytokine induced killer cell immunotherapy combined with S-1 in patients with advanced pancreatic cancer: A prospective study[J]. Clin Cancer Res, 2017,23(17):5066-5073. |
| [10] |
Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy[J]. Curr Opin Oncol, 2013,25(1):50-51.
pmid: 23150341 |
| [11] | Jaiswal M, LaRusso NF, Burgart LJ, et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism[J]. Cancer Res, 2000,60(1):184-190. |
| [12] |
He W, Yin C, Guo G, et al. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer[J]. Med Oncol, 2013,30(1):439.
pmid: 23307251 |
| [13] |
Luo G, Liu C, Cheng H, et al. Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors[J]. Oncol Lett, 2017,13(4):2454-2458.
pmid: 28454419 |
| [14] |
Chen Y, Yan H, Wang Y, et al. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma[J]. Sci Rep, 2017,7(1):753.
pmid: 28392554 |
| [15] |
Formica V, Morelli C, Ferroni P, et al. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin[J]. Cancer Biomark, 2016,17(3):335-345.
pmid: 27434293 |
| [16] |
Ren J, Di L, Song G, et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences[J]. Clin Transl Oncol, 2013,15(10):780-788.
pmid: 23359185 |
| [17] | 王艺, 王理伟. 胰腺癌患者免疫状态及免疫治疗进展[J]. 肿瘤, 2018,38(6):610-616. |
| [18] |
Meng Y, Yu Z, Wu Y, et al. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application[J]. Hum Vaccin Immunother, 2017,13(6):1-9.
pmid: 28301266 |
| [19] |
Chen J, Chen Y, Feng F, et al. Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer[J]. J Thorac Dis, 2018,10(12):6711-6721.
pmid: 30746216 |
| [20] |
Wang Q, Liu Y, Chen Y, et al. CD300LG improves the cytotoxic activity of CIK[J]. Cent Eur J Immunol, 2017,42(2):117-122.
pmid: 28860929 |
| [21] |
Xue P, Kanai M, Mori Y, et al. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients[J]. Cancer Med, 2014,3(2):406-415.
pmid: 24519894 |
| [22] |
Li Y, Wang C, Xu M, et al. Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer[J]. J Cancer Res Clin Oncol, 2017,143(5):861-871.
doi: 10.1007/s00432-016-2330-1 pmid: 28108815 |
| [23] |
Kusumanto YH, Dam WA, Hospers GA, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor[J]. Angiogenesis, 2003,6(4):283-287.
doi: 10.1023/B:AGEN.0000029415.62384.ba pmid: 15166496 |
| [24] |
Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape[J]. Cytokine Growth Factor Rev, 2007,18(1-2):171-182.
doi: 10.1016/j.cytogfr.2007.01.015 pmid: 17329145 |
| [25] |
Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3+ regulatory T cells affect the evelopment and progression of hepatocarcinogenesis[J]. Clin Cancer Res, 2007,13(3):902-911.
doi: 10.1158/1078-0432.CCR-06-2363 pmid: 17289884 |
| [1] | 付浩, 申潞艳, 黄冰洋, 马少华. 免疫治疗背景下食管鳞状细胞癌围手术期治疗的临床思考[J]. 北京大学学报（医学版）, 2026, 58(2): 266-271. |
| [2] | 张铃福, 陈明, 赵小宇, 王港, 崔龙, 凌晓锋, 王立新, 徐智, 郭丽梅, 侯纯升. 原发灶局限于胆囊壁内胆囊癌大体分型及其与预后和癌前病变的相关性[J]. 北京大学学报（医学版）, 2026, 58(1): 184-189. |
| [3] | 林文灏, 谢阳, 王芳晴, 王淑盈, 刘香君, 胡凡磊, 贾园. 基于B细胞单细胞转录组测序的干燥综合征分子分型[J]. 北京大学学报（医学版）, 2025, 57(6): 1032-1041. |
| [4] | 高雅静, 李正芳, 马梦思, 武丽君. SII和SIRI对白塞病葡萄膜炎的风险预测及疾病活动度和预后的评估[J]. 北京大学学报（医学版）, 2025, 57(6): 1067-1073. |
| [5] | 郭博达, 陆敏, 王国良, 张洪宪, 刘磊, 侯小飞, 赵磊, 田晓军, 张树栋. 肾透明细胞癌与非透明细胞癌伴静脉癌栓患者的临床病理特征及预后比较[J]. 北京大学学报（医学版）, 2025, 57(4): 644-649. |
| [6] | 秦秋实, 李蕊, 周妍希, 张玥, 韩铭, 朱鏐娈. 敲减Blimp1基因表达对CCl4诱导的小鼠肝纤维化模型早期肝损伤的保护作用[J]. 北京大学学报（医学版）, 2025, 57(4): 727-734. |
| [7] | 梁学军, 张凤霞, 靳婷, 祝静静. 长效重组人白介素2药物的生物学活性和抑瘤作用[J]. 北京大学学报（医学版）, 2025, 57(2): 253-261. |
| [8] | 李伟浩, 李晶, 张学民, 李伟, 李清乐, 张小明. 术中回收式自体输血对颈动脉体瘤切除术后肿瘤预后的影响[J]. 北京大学学报（医学版）, 2025, 57(2): 272-276. |
| [9] | 毛雅晴, 陈震, 于尧, 章文博, 刘洋, 彭歆. 2型糖尿病对口腔鳞状细胞癌患者预后的影响[J]. 北京大学学报（医学版）, 2024, 56(6): 1089-1096. |
| [10] | 赵亮, 史成龙, 马柯, 赵静, 王潇, 邢晓燕, 莫万星, 练益瑞, 高超, 李玉慧. 抗合成酶综合征重叠类风湿关节炎患者的免疫学特征[J]. 北京大学学报（医学版）, 2024, 56(6): 972-979. |
| [11] | 刘家骏, 刘国康, 朱玉虎. 免疫相关性重症肺炎1例[J]. 北京大学学报（医学版）, 2024, 56(5): 932-937. |
| [12] | 欧俊永,倪坤明,马潞林,王国良,颜野,杨斌,李庚午,宋昊东,陆敏,叶剑飞,张树栋. 肌层浸润性膀胱癌合并中高危前列腺癌患者的预后因素[J]. 北京大学学报（医学版）, 2024, 56(4): 582-588. |
| [13] | 刘帅,刘磊,刘茁,张帆,马潞林,田晓军,侯小飞,王国良,赵磊,张树栋. 伴静脉癌栓的肾上腺皮质癌的临床治疗及预后[J]. 北京大学学报（医学版）, 2024, 56(4): 624-630. |
| [14] | 虞乐,邓绍晖,张帆,颜野,叶剑飞,张树栋. 具有低度恶性潜能的多房囊性肾肿瘤的临床病理特征及预后[J]. 北京大学学报（医学版）, 2024, 56(4): 661-666. |
| [15] | 周泽臻,邓绍晖,颜野,张帆,郝一昌,葛力源,张洪宪,王国良,张树栋. 非转移性T3a肾细胞癌患者3年肿瘤特异性生存期预测[J]. 北京大学学报（医学版）, 2024, 56(4): 673-679. |
|
||
